Acs K, Miettinen JJ, Sergeev P, Heckel T, Diao Y, Witt-Mulder K, Thureson M, Bischler T, Huppunen ME, Suvela M, Obermüller J, Munawar U, Slipicevic A, Bargou RC, Lehmann F, Gelius SS, Norin S, Schjesvold F, Sonneveld P, Stühmer T, Heckman CA (2025)
Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
Exp Hematol Oncol, 14 (1), 138
DOI 10.1186/s40164-025-00729-1, PubMed 41437395

Askeland FB, Bugge VH, Rasmussen AM, Lysén A, Haukås E, Moksnes M, Eilertsen AL, Tsykunova G, Eiken BD, Leknes NM, Rolke J, Stavseth V, Samstad E, Hallstensen RF, Szatkowski D, Hansen AA, Nilsen AS, Slørdahl TS, Abdollahi P, Schjesvold F (2025)
Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma
Blood Cancer J, 15 (1), 214
DOI 10.1038/s41408-025-01407-5, PubMed 41429779

Nørgaard JN, Abildgaard N, Lysén A, Tsykunova G, Vangsted AJ, João C, Remen N, Osnes L, Stokke C, Connelly JP, Revheim MR, Schjesvold F (2025)
Progression-Free and Overall Survival After KRd Consolidation in FDG PET/CT Positive Patients After ASCT: A Phase II Study (CONPET)
Clin Lymphoma Myeloma Leuk (in press)
DOI 10.1016/j.clml.2025.10.020, PubMed 41314938